LANGERHANS CELL HISTIOCYTOSIS
Clinical trials for LANGERHANS CELL HISTIOCYTOSIS explained in plain language.
Never miss a new study
Get alerted when new LANGERHANS CELL HISTIOCYTOSIS trials appear
Sign up with your email to follow new studies for LANGERHANS CELL HISTIOCYTOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Global trial aims to tame rare childhood disease
Disease control OngoingThis study tests different treatments for children under 18 with Langerhans cell histiocytosis, a rare disease where immune cells build up and cause damage. The goal is to control the disease, prevent it from coming back, and reduce long-term problems like hormone issues or nerve…
Matched conditions: LANGERHANS CELL HISTIOCYTOSIS
Phase: PHASE2, PHASE3 • Sponsor: North American Consortium for Histiocytosis • Aim: Disease control
Last updated May 26, 2026 08:34 UTC
-
Experimental drug shows promise for rare immune disorder
Disease control OngoingThis study tested the drug clofarabine in 25 people with Langerhans cell histiocytosis (LCH) or related disorders that had returned or not improved with standard therapy. The goal was to see if the drug could shrink or eliminate disease. Participants received clofarabine and were…
Matched conditions: LANGERHANS CELL HISTIOCYTOSIS
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 26, 2026 08:33 UTC
-
Gene-Guided hope: pediatric MATCH trial aims to outsmart tough childhood cancers
Knowledge-focused OngoingThis study screens children and young adults (ages 1–21) with advanced solid tumors, lymphomas, or related disorders that have come back or not responded to standard therapy. Researchers analyze the genetic makeup of each patient's tumor to find specific mutations that can be tar…
Matched conditions: LANGERHANS CELL HISTIOCYTOSIS
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 22, 2026 13:52 UTC